Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2025)

Contineum Therapeutics has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $190.8 million for Q3 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $190.8 million for Q3 2025, down 11.66% from a year ago — trailing twelve months through Dec 2025 was $572.0 million (down 26.08% YoY), and the annual figure for FY2024 was $212.8 million, up 63.24%.
  • Liabilities and Shareholders Equity for Q3 2025 was $190.8 million at Contineum Therapeutics, up from $182.9 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CTNM hit a ceiling of $221.4 million in Q2 2024 and a floor of $123.6 million in Q1 2024.
  • Median Liabilities and Shareholders Equity over the past 3 years was $194.6 million (2025), compared with a mean of $184.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 63.24% in 2024 and later fell 17.38% in 2025.
  • Contineum Therapeutics' Liabilities and Shareholders Equity stood at $130.4 million in 2023, then skyrocketed by 63.24% to $212.8 million in 2024, then fell by 10.34% to $190.8 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $190.8 million (Q3 2025), $182.9 million (Q2 2025), and $198.3 million (Q1 2025) per Business Quant data.